Cargando…

Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT‐HF risk model

AIMS: We aimed to develop a risk prediction tool that incorporated both clinical events and worsening health status for patients with heart failure (HF) with reduced ejection fraction (HFrEF). Identifying patients with HFrEF at increased risk of a poor outcome may enable proactive interventions that...

Descripción completa

Detalles Bibliográficos
Autores principales:	DeVore, Adam D., Hill, Claude Larry, Thomas, Laine E., Albert, Nancy M., Butler, Javed, Patterson, J. Herbert, Hernandez, Adrian F., Williams, Fredonia B., Shen, Xian, Spertus, John A., Fonarow, Gregg C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787961/ https://www.ncbi.nlm.nih.gov/pubmed/34791838 http://dx.doi.org/10.1002/ehf2.13709

Ejemplares similares

Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP‐HF
por: Chapman, Brittany, et al.
Publicado: (2022)

Characteristics and Treatments of Patients Enrolled in the CHAMP‐HF Registry Compared With Patients Enrolled in the PARADIGM‐HF Trial
por: DeVore, Adam D., et al.
Publicado: (2018)

Association between sacubitril/valsartan initiation and real‐world health status trajectories over 18 months in heart failure with reduced ejection fraction
por: Thomas, Merrill, et al.
Publicado: (2021)

Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure
por: Khariton, Yevgeniy, et al.
Publicado: (2018)

Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP‐HF registry
por: Khariton, Yevgeniy, et al.
Publicado: (2020)

Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection Fraction
por: Harrington, Josephine, et al.
Publicado: (2023)

Initiation, Continuation, or Withdrawal of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction
por: Gilstrap, Lauren G., et al.
Publicado: (2017)

INTERVENE‐HF: feasibility study of individualized, risk stratification‐based, medication intervention in patients with heart failure with reduced ejection fraction
por: Zile, Michael R., et al.
Publicado: (2021)

Renin–angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta‐analysis
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2017)

Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines—Heart Failure
por: Kelly, Jacob P., et al.
Publicado: (2019)

Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction
por: Brownell, Nicholas K., et al.
Publicado: (2022)

Impact of adherence to guideline‐directed therapy on risk of death in HF patients across an ejection fraction spectrum
por: Chen, Xiaojing, et al.
Publicado: (2023)

Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS‐HF
por: Fudim, Marat, et al.
Publicado: (2020)

Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF)
por: Parikh, Riya R, et al.
Publicado: (2022)

Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study
por: Januzzi, James L., et al.
Publicado: (2022)

Use of Hydralazine‐Isosorbide Dinitrate Combination in African American and Other Race/Ethnic Group Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction
por: Golwala, Harsh B., et al.
Publicado: (2013)

Ejection fraction, B‐type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure
por: Greenberg, Barry, et al.
Publicado: (2019)

The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020)

The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction
por: Brownell, Nicholas K, et al.
Publicado: (2021)

Evidence-Based Process Performance Measures and Clinical Outcomes in Patients With Incident Heart Failure With Reduced Ejection Fraction: A Danish Nationwide Cohort Study
por: Schjødt, Inge, et al.
Publicado: (2022)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event
por: Carnicelli, Anthony P., et al.
Publicado: (2021)

Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction
por: Talha, Khawaja M., et al.
Publicado: (2022)

Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF
por: Ueland, Thor, et al.
Publicado: (2021)

Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization
por: Buggey, Jonathan, et al.
Publicado: (2017)

Representativeness of the GALACTIC‐HF Clinical Trial in Patients Having Heart Failure With Reduced Ejection Fraction
por: Mefford, Matthew T., et al.
Publicado: (2022)

Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF
por: Adamson, Carly, et al.
Publicado: (2022)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Timing of Postdischarge Follow‐Up and Medication Adherence Among Patients With Heart Failure
por: Chang, Leslie L., et al.
Publicado: (2018)

Presence of ´isolated´ tricuspid regurgitation should prompt the suspicion of heart failure with preserved ejection fraction
por: Mascherbauer, Julia, et al.
Publicado: (2017)

Patient Perspectives on Digital Interventions to Manage Heart Failure Medications: The VITAL-HF Pilot
por: Samsky, Marc D., et al.
Publicado: (2023)

Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
por: Miller, Robert J.H., et al.
Publicado: (2022)

Middle-aged female with blue nails and graying skin
por: DeVore, Ansley, et al.
Publicado: (2023)

Growing Evidence Linking Microvascular Dysfunction With Heart Failure With Preserved Ejection Fraction
por: Giamouzis, Gregory, et al.
Publicado: (2016)

Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction
por: Cannon, Jane A., et al.
Publicado: (2016)

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)
por: Jensen, Jesper, et al.
Publicado: (2019)

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
por: Polito, Maria Vincenza, et al.
Publicado: (2020)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e8v4kf037uac4ijd5b527h3ln3